Business Wire

B2BROKER

16.11.2023 13:11:30 CET | Business Wire | Press release

Share
New B2BinPay v18 Introduces Unified Account System and Massive UI Revisions

B2BinPay, the leading crypto payment processor, has once again raised the bar with its latest v18 solution update. Building upon the success of their previous v17 release, the company has introduced significant advancements for their clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116251906/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2BinPay v18 update introduces Account Merge - Unifying Merchant and Enterprise Models and streamlining onboarding and business management processes. The update also comes with a fully renewed front-end and enhanced regulatory compliance. (Graphic: Business Wire)

The new release boasts a unified account system, merging the Merchant and Enterprise models and making transaction management easier than ever before. Coupled with a revamped front end and reinforced regulatory compliance, B2BinPay continues to prioritise UX and security in this latest version.

Let’s explore these cutting-edge updates further.

Account Unification

This update brings about a new philosophy in how B2BinPay delivers its services by unifying the two business models (Merchant and Enterprise) into one user-friendly interface.

What exactly does this mean for B2BinPay's clients? It means a more streamlined and integrated experience, as the platform combines both the Merchant and Enterprise account functionality into one user-friendly interface, which means clients can now manage all their transactions within a single, unified system.

But the benefits don't stop there. The account unification also simplifies the registration process, making it easier for businesses to join the platform and use its services immediately. With equal conditions and a single, unified onboarding fee for all types of users, clients have the freedom to choose and transition between services as their business needs evolve without the worry of extra costs or complex administrative processes. With this new approach, businesses can focus on what truly matters – their growth.

Revamped Front-End and Richer Functionality

The v18 release features a redesigned front end that not only aligns with the sleek aesthetic of the B2Broker brand but also offers improved speed and security for users. The core features that have made B2BinPay a favourite among its users have been maintained, ensuring a smooth transition to the updated platform. Here are the sections that have been completely redesigned:

  • Wallets & Transfers

With a sleeker layout and optimised processes, users can quickly navigate through wallets & transfers sections without extra clicks and lengthy loadings. The update streamlines all financial operations, including payouts, bank withdrawals, and exchanges, providing a more seamless and time-saving experience for B2BinPay users.

  • Account Menu

The renewed Account Menu features an intuitive, more user-friendly and secure design. Users can now easily manage their preferences, control API permissions, and customise their profile from one central location. Additionally, the 2FA feature adds an extra layer of security to protect user accounts from unauthorised access.

The Payment Page has also been revamped to reflect the updated design philosophy of B2Broker. This ensures that all financial transactions are carried out in a protected environment.

  • Helpdesk

The updated Helpdesk provides a more streamlined and user-friendly experience for users. With a more defined schedule for multilingual support and new sticker notifications for incoming messages, users can now keep track of their inquiries more efficiently and receive timely responses from the B2BinPay team.

  • Rates Interface

The Rates interface has undergone several upgrades. One of the major changes is that Rates now have richer filtering and favourites options. Additionally, the section can now be accessed directly from the top-level menu instead of being hidden in Wallets.

  • Flexible Invoices

B2BinPay has removed the previous 7-day limit on merchant invoice expiration, allowing for customisation of timelines to fit each business's specific requirements better.

Complying with FATF Travel Rule

The v18 update brings enhanced Travel Rule compliance to the forefront. By partnering with Notabene, a leading provider of Travel Rule solutions, B2BinPay ensures strict adherence to the Financial Action Task Force (FATF) Travel Rules regulations.

The FATF Travel Rule requires VASPs, including B2BinPay, to collect and share personal information in cryptocurrency transactions to prevent money laundering and other unethical practices. New integration equipped B2BinPay with a robust system for detecting suspicious activities and eliminating fraud, providing clients with added peace of mind.

Final Remarks

In light of the growing popularity and acceptance of cryptocurrency, B2BinPay has established itself as a reliable and trustworthy solution in providing efficient crypto payment architecture for businesses. The launch of their v18 update showcases their commitment to constantly improving and expanding their services, staying ahead of market trends and regulatory standards.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116251906/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye